Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Haleon PLC ( (GB:HLN) ) is now available.
Haleon PLC announced that as of August 31, 2025, it has issued a total of 8,959,221,411 ordinary shares, with 3,880,205 held as treasury shares. This leaves 8,955,341,206 shares with voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £400.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects its strong financial performance and robust cash flow management, which are offset by technical indicators suggesting potential bearish momentum. The company faces challenges in North America, but its strategic focus on innovation and geographic growth supports a positive outlook. Valuation is moderate, offering a balanced risk-reward profile.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, specializing in products across six major categories including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 20,392,811
Technical Sentiment Signal: Hold
Current Market Cap: £32.5B
Learn more about HLN stock on TipRanks’ Stock Analysis page.